Hansa Biopharma AB (publ) (HNSA.ST)
SEK 21.5
(-1.74%)
SEK 21.5
(-1.74%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 844.9 Million SEK | 7.78% |
| 2022 | 783.92 Million SEK | 2651.49% |
| 2021 | 28.49 Million SEK | 4422.38% |
| 2020 | 630 Thousand SEK | -86.95% |
| 2019 | 4.82 Million SEK | 914.08% |
| 2018 | 476 Thousand SEK | 0.0% |
| 2017 | - SEK | -100.0% |
| 2016 | 4000.00 SEK | -91.84% |
| 2015 | 49 Thousand SEK | -46.15% |
| 2014 | 91 Thousand SEK | -30.53% |
| 2013 | 131 Thousand SEK | 0.0% |
| 2012 | - SEK | 0.0% |
| 2011 | - SEK | 0.0% |
| 2010 | - SEK | -100.0% |
| 2009 | 8 Million SEK | 0.0% |
| 2008 | - SEK | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 927.11 Million SEK | 9.73% |
| 2024 Q2 | 956.35 Million SEK | 3.15% |
| 2024 Q3 | 942.95 Million SEK | -1.4% |
| 2023 FY | 844.9 Million SEK | 7.78% |
| 2023 Q4 | 844.9 Million SEK | -8.41% |
| 2023 Q2 | 858.59 Million SEK | 5.07% |
| 2023 Q1 | 817.19 Million SEK | 4.24% |
| 2023 Q3 | 922.51 Million SEK | 7.44% |
| 2022 FY | 783.92 Million SEK | 2651.49% |
| 2022 Q3 | 783.93 Million SEK | 3043.28% |
| 2022 Q1 | 26.72 Million SEK | -6.21% |
| 2022 Q2 | 24.94 Million SEK | -6.67% |
| 2022 Q4 | 783.92 Million SEK | -0.0% |
| 2021 Q1 | 582 Thousand SEK | -7.62% |
| 2021 FY | 28.49 Million SEK | 4422.38% |
| 2021 Q3 | 16.39 Million SEK | -7.1% |
| 2021 Q4 | 28.49 Million SEK | 73.81% |
| 2021 Q2 | 17.64 Million SEK | 2931.79% |
| 2020 Q4 | 630 Thousand SEK | -56.4% |
| 2020 Q3 | 1.44 Million SEK | -45.45% |
| 2020 FY | 630 Thousand SEK | -86.95% |
| 2020 Q1 | 4.71 Million SEK | -2.4% |
| 2020 Q2 | 2.64 Million SEK | -43.77% |
| 2019 Q2 | 7.13 Million SEK | -23.23% |
| 2019 Q4 | 4.82 Million SEK | -20.71% |
| 2019 Q3 | 6.08 Million SEK | -14.61% |
| 2019 Q1 | 9.28 Million SEK | 1851.26% |
| 2019 FY | 4.82 Million SEK | 914.08% |
| 2018 Q1 | 652 Thousand SEK | 0.0% |
| 2018 Q2 | 668 Thousand SEK | 2.45% |
| 2018 Q4 | 476 Thousand SEK | -59.56% |
| 2018 Q3 | 1.17 Million SEK | 76.2% |
| 2018 FY | 476 Thousand SEK | 0.0% |
| 2017 Q4 | - SEK | -100.0% |
| 2017 Q1 | 559 Thousand SEK | 13875.0% |
| 2017 Q3 | 574 Thousand SEK | 1.23% |
| 2017 Q2 | 567 Thousand SEK | 1.43% |
| 2017 FY | - SEK | -100.0% |
| 2016 Q3 | 547 Thousand SEK | 1925.93% |
| 2016 Q4 | 4000.00 SEK | -99.27% |
| 2016 Q2 | 27 Thousand SEK | -28.95% |
| 2016 FY | 4000.00 SEK | -91.84% |
| 2016 Q1 | 38 Thousand SEK | -22.45% |
| 2015 Q4 | 49 Thousand SEK | -18.33% |
| 2015 Q3 | 60 Thousand SEK | -13.04% |
| 2015 Q2 | 69 Thousand SEK | -14.81% |
| 2015 Q1 | 81 Thousand SEK | -10.99% |
| 2015 FY | 49 Thousand SEK | -46.15% |
| 2014 Q1 | - SEK | -100.0% |
| 2014 Q2 | - SEK | 0.0% |
| 2014 Q4 | 91 Thousand SEK | 0.0% |
| 2014 FY | 91 Thousand SEK | -30.53% |
| 2013 Q1 | - SEK | 0.0% |
| 2013 FY | 131 Thousand SEK | 0.0% |
| 2013 Q4 | 131 Thousand SEK | 0.0% |
| 2013 Q3 | 131 Thousand SEK | 0.0% |
| 2013 Q2 | - SEK | 0.0% |
| 2012 Q2 | - SEK | 0.0% |
| 2012 FY | - SEK | 0.0% |
| 2012 Q4 | - SEK | 0.0% |
| 2011 FY | - SEK | 0.0% |
| 2011 Q4 | - SEK | 0.0% |
| 2011 Q2 | - SEK | 0.0% |
| 2010 Q2 | - SEK | 0.0% |
| 2010 FY | - SEK | -100.0% |
| 2010 Q4 | - SEK | 0.0% |
| 2009 Q2 | - SEK | 0.0% |
| 2009 Q4 | 8 Million SEK | 0.0% |
| 2009 FY | 8 Million SEK | 0.0% |
| 2008 Q4 | - SEK | 0.0% |
| 2008 FY | - SEK | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Alzinova AB (publ) | 800 Thousand SEK | -105512.875% |
| Amniotics AB (publ) | - SEK | -Infinity% |
| Asarina Pharma AB (publ) | 1 Million SEK | -84390.3% |
| BioArctic AB (publ) | 2.15 Million SEK | -39161.292% |
| Calliditas Therapeutics AB (publ) | 939.5 Million SEK | 10.07% |
| Genovis AB (publ.) | 74.8 Million SEK | -1029.429% |
| LIDDS AB (publ) | - SEK | -Infinity% |
| Magle Chemoswed Holding AB (publ) | 32.58 Million SEK | -2493.159% |
| OncoZenge AB (publ) | - SEK | -Infinity% |
| Saniona AB (publ) | 65.23 Million SEK | -1195.109% |
| Simris Alg AB (publ) | 90.74 Million SEK | -831.125% |
| Vicore Pharma Holding AB (publ) | - SEK | -Infinity% |
| AcouSort AB (publ) | - SEK | -Infinity% |
| Active Biotech AB (publ) | 3 Million SEK | -28063.433% |
| Camurus AB (publ) | 13.61 Million SEK | -6106.589% |
| Cantargia AB (publ) | - SEK | -Infinity% |
| Scandinavian ChemoTech AB (publ) | - SEK | -Infinity% |
| Guard Therapeutics International AB (publ) | - SEK | -Infinity% |
| Mendus AB (publ) | 850 Thousand SEK | -99300.353% |
| Kancera AB (publ) | - SEK | -Infinity% |
| Karolinska Development AB (publ) | - SEK | -Infinity% |
| Lipum AB (publ) | 1.76 Million SEK | -47878.592% |
| Lipigon Pharmaceuticals AB (publ) | - SEK | -Infinity% |
| NextCell Pharma AB | - SEK | -Infinity% |
| Xbrane Biopharma AB (publ) | 112.89 Million SEK | -648.384% |
| Xintela AB (publ) | - SEK | -Infinity% |
| Ziccum AB (publ) | 286 Thousand SEK | -295320.629% |
| Elicera Therapeutics AB (publ) | - SEK | -Infinity% |
| Modus Therapeutics Holding AB (publ) | - SEK | -Infinity% |
| Isofol Medical AB (publ) | - SEK | -Infinity% |
| Xspray Pharma AB (publ) | 31.94 Million SEK | -2544.702% |
| CombiGene AB (publ) | - SEK | -Infinity% |
| Diamyd Medical AB (publ) | 30.67 Million SEK | -2654.639% |
| Intervacc AB (publ) | 142 Thousand SEK | -594902.113% |
| Alligator Bioscience AB (publ) | 7.51 Million SEK | -11141.392% |
| Sprint Bioscience AB (publ) | - SEK | -Infinity% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | - SEK | -Infinity% |
| Corline Biomedical AB | - SEK | -Infinity% |
| IRLAB Therapeutics AB (publ) | 24.51 Million SEK | -3347.036% |
| Bio-Works Technologies AB (publ) | - SEK | -Infinity% |
| Aptahem AB (publ) | - SEK | -Infinity% |
| Infant Bacterial Therapeutics AB (publ) | - SEK | -Infinity% |
| Fluicell AB (publ) | - SEK | -Infinity% |
| Biovica International AB (publ) | 4.29 Million SEK | -19567.202% |
| Spago Nanomedical AB (publ) | - SEK | -Infinity% |
| Abliva AB (publ) | 424 Thousand SEK | -199169.575% |
| Egetis Therapeutics AB (publ) | 103.4 Million SEK | -717.121% |
| 2cureX AB (publ) | - SEK | -Infinity% |
| I-Tech AB | - SEK | -Infinity% |
| Cyxone AB (publ) | 74 Thousand SEK | -1141660.811% |
| ExpreS2ion Biotech Holding AB (publ) | 1.43 Million SEK | -58737.256% |
| Biosergen AB | - SEK | -Infinity% |
| Nanologica AB (publ) | 136 Thousand SEK | -621152.206% |
| SynAct Pharma AB | 58 Thousand SEK | -1456629.31% |
| Annexin Pharmaceuticals AB (publ) | - SEK | -Infinity% |
| BioInvent International AB (publ) | 14.53 Million SEK | -5712.886% |
| Stayble Therapeutics AB (publ) | 850 Thousand SEK | -99300.353% |
| Oncopeptides AB (publ) | 106.48 Million SEK | -693.433% |
| Pila Pharma AB (publ) | - SEK | -Infinity% |
| Ascelia Pharma AB (publ) | 176 Thousand SEK | -479958.523% |
| Diagonal Bio AB (publ) | - SEK | -Infinity% |